Company Quick10K Filing
Zoetis
10-Q 2020-03-31 Filed 2020-05-06
10-K 2019-12-31 Filed 2020-02-13
10-Q 2019-09-30 Filed 2019-11-07
10-Q 2019-08-06 Filed 2019-08-06
10-Q 2019-03-31 Filed 2019-05-02
10-K 2018-12-31 Filed 2019-02-14
10-Q 2018-09-30 Filed 2018-11-01
10-Q 2018-06-30 Filed 2018-08-02
10-Q 2018-03-31 Filed 2018-05-02
10-K 2017-12-31 Filed 2018-02-15
10-Q 2017-10-01 Filed 2017-11-02
10-Q 2017-07-02 Filed 2017-08-08
10-Q 2017-04-02 Filed 2017-05-04
10-K 2016-12-31 Filed 2017-02-16
10-Q 2016-10-02 Filed 2016-11-03
10-Q 2016-07-03 Filed 2016-08-05
10-Q 2016-04-03 Filed 2016-05-06
10-K 2015-12-31 Filed 2016-02-24
10-Q 2015-09-27 Filed 2015-11-05
10-Q 2015-06-28 Filed 2015-08-06
10-Q 2015-03-29 Filed 2015-05-07
10-K 2014-12-31 Filed 2015-02-27
10-Q 2014-09-28 Filed 2014-11-10
10-Q 2014-06-29 Filed 2014-08-12
10-Q 2014-03-30 Filed 2014-05-13
10-K 2013-12-31 Filed 2014-03-26
10-Q 2013-09-29 Filed 2013-11-13
10-Q 2013-06-30 Filed 2013-08-14
10-Q 2013-03-31 Filed 2013-05-15
10-K 2012-12-31 Filed 2013-03-28
8-K 2020-05-20
8-K 2020-05-20
8-K 2020-05-12
8-K 2020-05-06
8-K 2020-02-13
8-K 2020-02-11
8-K 2019-12-11
8-K 2019-12-09
8-K 2019-11-07
8-K 2019-10-03
8-K 2019-10-02
8-K 2019-08-06
8-K 2019-05-15
8-K 2019-05-02
8-K 2019-02-14
8-K 2019-02-12
8-K 2018-12-12
8-K 2018-11-01
8-K 2018-10-10
8-K 2018-08-20
8-K 2018-08-02
8-K 2018-07-31
8-K 2018-07-27
8-K 2018-07-06
8-K 2018-05-16
8-K 2018-05-15
8-K 2018-05-02
8-K 2018-02-15
8-K 2018-02-13
8-K 2018-01-08

Zoetis Financials

ZTS Metrics, Comps, Filings

Quarterly | Annual

Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Equity

Income Statement ($BB Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($BB Quarterly)

Ops, Inv, Fin

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
AbbVie (ABBV) 109,786 77% 21.1 5% 59,441 67,667 32,867 25,412 3,255 6,259 132,264
Eli Lilly (LLY) 105,897 78% 12.7 21% 37,893 34,431 22,644 17,612 7,948 9,419 119,560
Beigene (BGNE) 100,124 74% -123.1 -44% 1,881 587 430 318 -827 -807 99,328
Bristol Myers Squibb (BMY) 82,160 70% 10.6 10% 57,433 39,679 24,173 16,837 5,680 7,151 76,061
Celgene (CELG) 72,111 96% 10.4 14% 41,363 29,276 16,982 16,354 5,880 7,734 80,796
Zoetis (ZTS) 60,799 51% 29.1 13% 11,272 8,594 6,150 3,124 1,461 2,252 65,484
Allergan (AGN) 54,957 63% -241.2 -5% 122,925 38,486 15,818 9,949 -5,872 -316 76,270
Sanofi (SNY) 52,845 0% 111,408 0 0 0 0 52,184
GW Pharmaceuticals (GWPH) 45,954 89% -870.1 -8% 848 128 205 182 -64 -52 45,400
Vertex Pharmaceuticals (VRTX) 43,431 87% 46.7 29% 7,515 2,261 3,620 3,135 2,144 857 40,027
Regeneron Pharmaceuticals (REGN) 32,266 0% 12.2 15% 13,939 3,435 7,622 0 2,144 2,539 30,869
Alexion Pharmaceuticals (ALXN) 23,581 92% 12.8 10% 14,815 4,448 4,736 4,359 1,470 1,874 23,912
Biomarin Pharmaceutical (BMRN) 12,700 79% 1,194.1 -1% 4,558 1,484 1,250 986 -39 11 13,147
Mylan (MYL) 10,768 34% 12.5 -0% 31,054 19,590 8,309 2,810 -4 1,882 23,458
Elanco Animal Health (ELAN) 9,964 52% 30.6 1% 8,824 3,336 3,083 1,611 94 393 12,004
Alnylam Pharmaceuticals (ALNY) 8,913 80% -9.7 -32% 2,542 935 169 135 -821 -820 7,987
Ionis Pharmaceuticals (IONS) 8,784 76% 17.4 15% 2,895 1,397 821 626 436 491 8,536
Bausch (BHC) 7,760 0% 25.3 -1% 31,667 29,107 8,498 0 -266 1,216 30,774
Jazz Pharmaceuticals (JAZZ) 7,549 21% 11.2 11% 5,528 2,473 2,056 441 609 762 8,530
Perrigo (PRGO) 7,421 37% 17.9 2% 11,311 5,552 4,710 1,735 247 580 10,388

Balance Sheet ($MM)2013-03-312013-06-302013-09-292013-12-312014-03-302014-06-292014-09-282014-12-312015-03-292015-06-282015-09-272015-12-312016-04-032016-07-032016-10-022016-12-312017-04-022017-07-022017-10-012017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-08-062019-09-30
Cash4683693896105065785988825595445921,1546756586517276297051,9811,5641,6541,5581,2861,6021,7281,7551,815
Accounts Receivable8611,1371,1101,1381,1001,0981,0579809059931,0389379088889159139549751,0099989439739291,0369709941,030
Inventory1,1201,2571,2901,2931,3161,3361,3881,2891,3461,4171,4031,4671,4611,5251,5631,5021,5351,4981,4901,4271,4411,4201,4411,3911,3611,4041,439
PP&E1,2371,2521,2522,3231,2921,3091,3132,4631,3011,2951,2932,5151,3171,3411,3822,7391,3681,3551,3882,9061,4531,4701,5563,2571,6831,7391,813
Assets6,1426,2616,2596,5586,4036,5226,5276,6076,4306,5986,6867,9137,4537,5187,7157,6497,6497,8029,2888,5868,6908,60310,45910,77710,88310,98611,272
Accounts Payable275587482506363337259290256278306293210224241265231199213261217230238313235290284
Long-Term Debt3,6503,6503,6523,6523,6523,6523,6523,6533,6523,6523,6524,9004,5004,5004,5014,5004,5004,5005,7505,0005,0005,0006,5006,5006,5006,5006,500
Liabilities5,4185,4385,3935,5965,3045,2395,1385,2705,1255,3965,4326,8226,2666,1476,1176,1506,0146,0567,2696,8006,7156,6218,3418,5928,5668,5758,594
Stockholders' Equity7098008439401,0771,2601,3641,3111,2781,1761,2291,0681,1651,3571,5851,4871,6091,7151,9891,7701,9601,9702,1182,185
Income Statement ($MM)2013-03-312013-06-302013-09-292013-12-312014-03-302014-06-292014-09-282014-12-312015-03-292015-06-282015-09-272015-12-312016-04-032016-07-032016-10-022016-12-312017-04-022017-07-022017-10-012017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-08-062019-09-30
Revenue1,0901,1141,1031,2541,0971,1581,2101,3201,1021,1751,2141,2741,1621,2081,2411,2771,2311,2691,3471,4601,3661,4151,4801,5641,4551,5471,584
Cost of Revenue402416385466379413434491394427421496389399410468443440435457447447473518465479
Gross Profit6886987187887187457768297087487937787738098318097888299121,0039199681,0079371,0821,105
R&D90959312187929312480849110990889010890869611097102108102111112
SG&A357399399458356396394497354379374425315343345361309336328361338359367369406391
Tax52595457727471296598349128108967798219117350671797173698495
Net Income140128131105155160167126165-361902220422423915423924729881352384347345312371433
Cash Flow ($MM)2013-03-312013-06-302013-09-292013-12-312014-03-302014-06-292014-09-282014-12-312015-03-292015-06-282015-09-272015-12-312016-04-032016-07-032016-10-022016-12-312017-04-022017-07-022017-10-012017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-08-062019-09-30
Cash Operating281-12114298-231591033876012220427851137239286119180439608389267550389318506
Cash Investing-22-52-54-51-45-50-42-50-274-44-60-73718-49-124-59-48-40-128-54-45-76-2,064-23-59-209
Cash Financing-108-32-32-28-35-39-38-42-94-91-861,026-543-108-124-128-176-64956-967-262-2711,263-243-226-232